3 patents
Utility
Triple Combination to Treat B-cell Malignancies
12 May 22
Methods for treating B-cell malignancies are provided comprising administering a triple combination of agents, comprising: (i) a PI3K-delta selective inhibitor (e.g., umbralisib); (ii) an anti-CD20 antibody (e.g., ublituximab); and (iii) the Bruton's tyrosine kinase (BTK) inhibitor TG-1701.
Michael S. WEISS, Hari P. MISKIN, Peter SPORTELLI
Filed: 12 Nov 21
Utility
Combination of ANTI-CD20 Antibody, P13 Kinase-delta Selective Inhibitor, and BTK Inhibitor to Treat B-cell Proliferative Disorders
10 Jun 21
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor.
Michael S. WEISS, Hari P. MISKIN, Peter SPORTELLI
Filed: 12 Feb 21
Utility
Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor
14 Oct 20
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorders.
Michael S. Weiss, Hari P. Miskin, Peter Sportelli, Swaroop K.V.S. Vakkalanka
Filed: 28 Jun 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first